Dystrophie musculaire de Duchenne Dystrophie musculaire de Duchenne Dystrophie musculaire de Duchenne

Archives

Monthly Archive for: "May, 2021"
ENDEAVOR, gene therapy for DMD
By Marie
In News, Research, Treatments
Posted 20 May 2021

ENDEAVOR, gene therapy for DMD

Sarepta Therapeutics’ investigational gene therapy for the treatment of Duchenne muscular dystrophy, SRP-9001, demonstrates robust expression and consistent safety profile using Sarepta’s [...]
Positive clinical results from phase 2 MOMENTUM study
By Marie
In News, Research, Treatments
Posted 4 May 2021

Positive clinical results from phase 2 MOMENTUM study

Sarepta Therapeutics reports positive clinical results from phase 2 MOMENTUM study of SRP-5051 in patients with Duchenne muscular dystrophy amenable to skipping exon 51 Results suggest a highly [...]

Articles récents

  • The global day of giving
  • EMBARK, gene therapy for the treatment of DMD
  • Part B of MOMENTUM study of SRP-5051 in patients with DMD
  • World Duchenne Awareness Day 2021
  • ENDEAVOR, gene therapy for DMD

Catégories

  • Fundraising
  • in the Medias
  • News
  • Research
  • Testimonial
  • Treatments

+

Restez informé

    LA Force - Dystrophie musculaire de Duchenne

    La Force dmd - Tous droits réservés - Organisme de bienfaisance enregistré : 817683568RP0001
    La Force dmd La Force dmd
    • S’informer
      • Frequently Asked Questions
    • Make a Donation
    • Agir
      • Quick guige – Management of DMD
      • Take action – What’s your genetic profile?
      • Take action – Subscribe to registries
    • Aller plus loin
      • Go further – How can you access a new treatment?
      • Go further – How do researchers test new treatments?
      • Go further – How are drugs approved for use in Canada?
      • Go further – Who decides to reimburse drug costs?
    • Blog
    • About us
    • Contact-us